Mirum Pharmaceuticals logo
Mirum Pharmaceuticals MIRM
$ 41.86 1.76%

Quarterly report 2024-Q3
added 11-12-2024

report update icon

Mirum Pharmaceuticals Balance Sheet 2011-2024 | MIRM

Annual Balance Sheet Mirum Pharmaceuticals

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-285 M -25.8 M -28.7 M -137 M -8.32 M -52 M - - - - - - -

Long Term Debt

617 K 1.26 M 1.9 M 2.63 M - - - - - - - - -

Long Term Debt Current

1.1 M 931 K 711 K 636 K 397 K - - - - - - - -

Total Non Current Liabilities

- - - 50.3 M 3.29 M 59.8 M - - - - - - -

Total Current Liabilities

87.1 M 64.7 M 42.6 M 18.5 M 13.1 M - - - - - - - -

Total Liabilities

398 M 211 M 174 M 68.8 M 16.4 M 62.3 M - - - - - - -

Deferred Revenue

- - - - - - - - - - - - -

Retained Earnings

-556 M -393 M -257 M -173 M -69.9 M -17.3 M - - - - - - -

Total Assets

647 M 353 M 295 M 241 M 147 M 52 M - - - - - - -

Cash and Cash Equivalents

286 M 28 M 31.3 M 142 M 12 M - - - - - - - -

Book Value

249 M 142 M 120 M 172 M 130 M -10.3 M - - - - - - -

Total Shareholders Equity

249 M 142 M 120 M 172 M 130 M -17.3 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Mirum Pharmaceuticals

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

8.48 M 8.24 M 328 K 617 K 868 K 1.15 M 1.06 M 1.26 M 1.31 M - 1.71 M 1.9 M 2.09 M 2.27 M 2.45 M 2.63 M 2.63 M 2.63 M 2.63 M 3.25 M 3.25 M 3.25 M 3.25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

436 M 432 M 417 M 398 M 382 M 365 M 192 M 211 M 195 M - 169 M 174 M 179 M 152 M 88.4 M 68.8 M 68.8 M 68.8 M 68.8 M 16.4 M 16.4 M 16.4 M 16.4 M 2.45 M 2.45 M 2.45 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-620 M -606 M -582 M -556 M -521 M -497 M -423 M -393 M -356 M - -294 M -257 M -315 M -268 M -224 M -173 M -173 M -173 M -173 M -69.9 M -69.9 M -69.9 M -69.9 M -17.3 M -17.3 M -17.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

668 M 661 M 652 M 647 M 651 M 444 M 334 M 353 M 364 M - 278 M 295 M 235 M 248 M 222 M 241 M 241 M 241 M 241 M 147 M 147 M 147 M 147 M 52 M 52 M 52 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

223 M 233 M 303 M 286 M 303 M 297 M 49.4 M 28 M 35.8 M - 46.3 M 31.3 M 55.8 M 91.9 M 90.7 M 142 M 142 M 142 M 142 M 12 M 12 M 12 M 12 M 52 M 52 M 52 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

232 M 229 M 235 M 249 M 269 M 78.6 M 141 M 142 M 169 M - 109 M 120 M 56.4 M 95.7 M 134 M 172 M 172 M 172 M 172 M 130 M 130 M 130 M 130 M 49.5 M 49.5 M 49.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

232 M 229 M 235 M 249 M 269 M 78.6 M 141 M 142 M 169 M 111 M 109 M 120 M 56.4 M 95.7 M 134 M 172 M 172 M 172 M 172 M 130 M 130 M 130 M 130 M -17.3 M -17.3 M -17.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency